
Alnylam Jumps As A New Approval Sets Up Its Next Battle With Pfizer, BridgeBio
Alnylam stock jumped Friday after the drugmaker won a second Food and Drug Administration approval for its drug, Amvuttra. Amvuttra was already approved to treat patients with transthyretin amyloid polyneuropathy, a rare disease in which abnormal protein …